Healthcare / BiotechnologyNasdaqCM
$1.19
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-24.6M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$103M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-169.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-26.6M · FCF $-25.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | $4.0M | $8.9M | $3.4M | $1.6M |
| Net Income | $-26.6M | $-26.6M | $-23.5M | $-25.7M | $-13.9M | $-12.8M | $-14.9M | $-33.6M | $-35.1M | $-28.5M | $-33.2M | $-20.0M | $-35.2M | $-23.0M |
| EBITDA | $-27.1M | $-27.1M | $-24.3M | $-26.6M | $-20.9M | $-13.0M | $-14.7M | $-33.6M | $-34.7M | $-28.2M | $-32.8M | $-19.7M | $-21.0M | $-17.7M |
| EPS | -0.43 | -0.43 | -0.43 | -0.50 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | -152.3% | 41.1% | -4.7% | -259.7% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | -830.3% | -225.2% | -624.5% | -1150.0% |
| Net Margin | — | — | — | — | — | — | — | — | — | — | -829.5% | -224.9% | -1035.3% | -1467.7% |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-25.5M | $-25.5M | $-21.3M | $-24.6M | $-19.1M | $-11.5M | $-17.2M | $-28.1M | $-30.0M | $-24.2M | $-25.6M | $-21.3M | — | — |
| Returns | ||||||||||||||
| ROE | -169.2% | -169.2% | -133.4% | -123.6% | -31.3% | -518.2% | -763.1% | -461.7% | -1137.9% | -361.8% | -297.6% | -98.8% | -101.7% | 249.1% |
| Growth & Yield | ||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | — | — | -55.1% | 161.8% | 117.3% | — |
| EPS Growth | 0.0% | 0.0% | 14.0% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.